Are there predictors of Remicade treatment success or failure?
- 6 January 2005
- journal article
- review article
- Published by Elsevier BV in Advanced Drug Delivery Reviews
- Vol. 57 (2), 237-245
- https://doi.org/10.1016/j.addr.2004.08.006
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's diseaseGastroenterology, 2003
- CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD)Gastroenterology, 2003
- A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in crohn diseaseGastroenterology, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Impatient and outpatient costs of care for inflammatory bowel disease in the year 2000Gastroenterology, 2001
- Prediction of response to treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's diseaseGastroenterology, 2001
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993